MELVILLE (dpa-AFX) - Atlas Genomics, a privately held CLIA-certified high complexity molecular diagnostic laboratory located in Seattle, Washington, announced an agreement with Henry Schein Medical, the U.S. Medical business of Henry Schein, Inc. (HSIC), under which Henry Schein Medical will offer its customers Noninvasive Prenatal Testing (NIPT) and Carrier Screening by Atlas Genomics on an exclusive basis.
Noninvasive prenatal screening (NIPT), also called prenatal cell-free DNA (cfDNA) screening, is a method to screen for certain specific chromosomal abnormalities in a developing baby, including trisomy abnormalities.
During prenatal cell-free DNA screening, DNA from the mother and fetus is extracted from a maternal blood sample to screen for the increased chance for specific chromosome problems, such as Down syndrome.
Copyright RTT News/dpa-AFX